ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). DoR (mo), median (95% CI) 7.6 (5.4-9.7) 6.3 (3.9-9.7) 8.4 (4.6-12.7) 8.2 (5.4-11.7) PFS ...
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received ...
“Now we have chemotherapy-free immunotherapy options for patients whose myeloma has relapsed for the first time,” said senior ...
Presence of hyperdiploidy and history of tobacco use in African American patients with SMM. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...
Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall. | Bristol Myers Squibb may have gone big in ...
Morning Overview on MSN
The FDA just cleared Beqalzi for mantle cell lymphoma — sonrotoclax becoming the latest targeted therapy for a relapsed blood cancer with few options
Adults with mantle cell lymphoma who have already failed two or more treatments, including a BTK inhibitor, now have a new ...
Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results